Despite a rocky quarter for public equities, the medtech sector showed relative resilience in Q1 2025. While broader indexes such as the S&P 500 and Nasdaq posted losses, about half of large public medtech companies managed to log gains—boosting the sector’s median performance above the market average. Volatility was sharpest in life sciences, with Tempus AI surging before pulling back and Illumina tumbling more than 45%. Analysts expect double-digit revenue growth in diagnostics, consumer health, and medical devices—although those forecasts may shift as first-quarter earnings roll in.
Read the full article: PitchBook’s Q1 2025 Medtech Public Comp Sheet and Valuation Guide //
Source: https://pitchbook.com/news/reports/q1-2025-medtech-public-comp-sheet-and-valuation-guide